CDC logoSafer Healthier People CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Skip navigation links Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us

NIOSH Program Portfolio

 

Manufacturing

NORA Manufacturing Sector Strategic Goals

9277278 - Revised REL for Glutaraldehyde

Start Date: 10/1/1999
End Date: 9/30/2011

Principal Investigator (PI)
Name: Kathleen Macmahon
Phone: 513-533-8547
E-mail: kqm1@cdc.gov
Organization: NIOSH
Sub-Unit: EID
Funded By: NIOSH

Primary Goal Addressed
5.0

Secondary Goal Addressed
None


Attributed to Manufacturing
50%

Project Description

Short Summary

The purpose of this project is to develop a policy document to update the existing REL for glutaraldehyde [NIOSH,1988]. Contact dermatitis and asthma have been noted in workers with exposure below the existing NIOSH REL (0.2 ppm, ceiling). In accordance with NIOSH's mission to assure a safe and healthful workplace, a policy document will be developed to provide a summary of the relevant health effects data, a revised REL and guidelines to reduce the risk of adverse health effects in workers across two NORA sectors (manufacturing and health care). This revised REL will commit the latest research to the practice of protecting working men and women from the health effects of occupational glutaraldehyde exposure.



Description

The purpose of this project is to develop a policy document to update the existing Recommended Exposure Limit (REL) for glutaraldehyde [NIOSH 1988]. This update will use as primary resources, the 1997 criteria document of the Health and Safety Executive (HSE) of the United Kingdom on glutaraldehyde, and the recently released document entitled, Health-based Recommended Occupational Exposure Limit: Glutaraldehyde published jointly by the Nordic Expert Group (NEG) and the Dutch Expert Committee for Occupational Standards (DECOS). The NIOSH document, under development, will provide a concise summary of the relevant health effects data, a revised REL, sampling and analytical methods, workplace exposure data, and engineering controls and work practices. It is intended for safety and health professionals in health care settings (i.e., dental, hospital, mortuary, etc.), academia, labor, industry, public interest groups, and other government agencies. Partnerships will be developed with these groups to ensure their understanding of the updated REL and the completeness of the data used as the basis for its revision. This project focuses on two NORA sectors (manufacturing, and health care and social assistance) and translates research into practice for safety and health professionals, employers, and workers.



The proposed schedule is:



FY00-01 - Formed internal/external partnerships with OSHA, Dow (formerly Union Carbide), N.J. Department of Health; Health and Safety Executive (UK), and the Dutch Expert Committee (DECOS).

FY02-03: Literature review/evaluation completed.

FY04-05: Identified relevant health effects, use, and exposure data; prepared first draft.

FY08: NIOSH internal review.

FY09: External and OMB review.

FY09-10: Publish document.



Objectives

Concern exists that the current recommended exposure limit (REL) of 0.2 parts per million (ceiling) does not provide sufficient protection against glutaraldehyde hazards as significant health effects such as contact dermatitis and asthma have been noted in workers with exposure below the REL. The objective of this project is to develop a concise policy document to reduce or eliminate adverse health effects in these workers during glutaraldehyde manufacturing and use.



Mission Relevance

The National Occupational Exposure Survey reported more than 367,000 workers with possible glutaraldehyde exposure through its manufacture and its use in various health care industries. Scientific literature reports that glutaraldehyde causes sensory irritation (eyes, nose, respiratory tract), and possibly contact dermatitis, skin sensitization, and asthma. The current REL (0.2 ppm, ceiling) may not protect sufficiently against glutaraldehyde hazards as contact dermatitis and asthma have been noted in workers exposed below the REL. This policy document will provide an updated summary of the relevant health effects data, a revised REL and guidelines to reduce the risk of adverse health effects in the exposed workers during glutaraldehyde manufacture and use. The revised REL will be transmitted to OSHA, MSHA, and other regulatory agencies for use in future rulemaking. In accordance with NIOSH's mission to assure a safe and healthful workplace, this cross-cutting research to practice project will assist in protecting working men and women from the health effects of occupational glutaraldehyde exposure in the NORA sectors of manufacturing.

Sector Programs

Health Care and Social Assistance

09PPHSASG2

Strategic Goal 2: Reduce or eliminate noninfectious hazardous exposures and health consequences for workers in the healthcare and social assistance sector.



Healthcare Strategic subgoal 2f (09PPHSAIG2f): Reduce adverse outcomes caused by exposures to allergens and irritants.



Healthcare Activity/Output Goal 2f.1.1 (09PPHSAAOG2f1.1): Reduce dermatologic consequences of exposures to allergens and irritants.



Healthcare Strategic subgoal 2g (09PPHSAIG2g): Reduce respiratory consequences of exposures to allergens.



Manufacturing

09PPMNFSG5

Strategic Goal 5: Reduce the number of respiratory conditions and diseases due to exposures in the manufacturing sector.



Cross Sector Health Outcome Programs

Strategic Goal 1 (09PPRDRSG1):

Prevent and reduce work-related airways diseases.

It should be noted that surveillance is critical to the intermediate goals (IG) and output goals (OG) supporting the airways diseases strategic goal. Surveillance is needed to document baseline conditions and the impact of intervention and prevention efforts. Education, communication, information dissemination, and providing support to standard-setting and regulatory groups are also critical to achieving intermediate outcomes that demonstrate impact.

Intermediate Goal (09PPRDRIG1.1): prevent and reduce the full range of work-related asthma (WRA), including work-exacerbated asthma; occupational asthma; and irritant-induced asthma.



Other Sector Programs

Authorative Recommendation Development

09PPAURSG1

Strategic Goal 1: Reduce and prevent occupational injuries, illnesses, and fatalities by supporting NORA sector and cross-sector programs in the development of authoritative recommendations.



Page last updated: June 3, 2011
Page last reviewed: May 23, 2011
Content Source: National Institute for Occupational Safety and Health (NIOSH) Office of the Director

 

NIOSH Program:

Manufacturing